Medigene AG - Asset Resilience Ratio
Medigene AG (MDG1) has an Asset Resilience Ratio of 25.22% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MDG1 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Medigene AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medigene AG asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Medigene AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Medigene AG to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €8.00 Million | 25.22% |
| Total Liquid Assets | €8.00 Million | 25.22% |
Asset Resilience Insights
- Very High Liquidity: Medigene AG maintains exceptional liquid asset reserves at 25.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medigene AG Industry Peers by Asset Resilience Ratio
Compare Medigene AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Medigene AG (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Medigene AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 25.22% | €8.00 Million ≈ $9.35 Million |
€31.72 Million ≈ $37.08 Million |
-39.07pp |
| 2022-12-31 | 64.29% | €33.22 Million ≈ $38.84 Million |
€51.68 Million ≈ $60.42 Million |
+26.60pp |
| 2021-12-31 | 37.69% | €22.42 Million ≈ $26.21 Million |
€59.47 Million ≈ $69.53 Million |
-2.48pp |
| 2020-12-31 | 40.18% | €30.03 Million ≈ $35.11 Million |
€74.75 Million ≈ $87.39 Million |
-9.89pp |
| 2019-12-31 | 50.07% | €54.68 Million ≈ $63.93 Million |
€109.22 Million ≈ $127.68 Million |
+10.40pp |
| 2018-12-31 | 39.67% | €51.41 Million ≈ $60.10 Million |
€129.59 Million ≈ $151.50 Million |
-6.54pp |
| 2017-12-31 | 46.21% | €51.72 Million ≈ $60.47 Million |
€111.94 Million ≈ $130.87 Million |
-0.90pp |
| 2016-12-31 | 47.11% | €52.63 Million ≈ $61.53 Million |
€111.72 Million ≈ $130.61 Million |
+13.64pp |
| 2015-12-31 | 33.47% | €38.00 Million ≈ $44.43 Million |
€113.53 Million ≈ $132.73 Million |
+33.22pp |
| 2014-12-31 | 0.25% | €180.00K ≈ $210.44K |
€71.28 Million ≈ $83.34 Million |
-0.04pp |
| 2013-12-31 | 0.29% | €154.00K ≈ $180.04K |
€52.66 Million ≈ $61.56 Million |
-0.30pp |
| 2012-12-31 | 0.59% | €362.00K ≈ $423.22K |
€61.26 Million ≈ $71.61 Million |
-- |
About Medigene AG
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its lead product includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications. The company also develop… Read more